Efficacy of 10 IU Syntocinon versus 800 µg Misoprostol Sublingual in Active Management of 3rd Stage of Labour
Article Sidebar
Main Article Content
Abstract
Background: The active management of the third stage of labor is crucial for preventing postpartum hemorrhage (PPH), a leading cause of maternal mortality. Syntocinon (oxytocin) and Misoprostol are prominent pharmacological agents used to manage this stage by inducing uterine contractions and minimizing blood loss.
Objective: This study aimed to compare the efficacy of 10 IU intravenous Syntocinon and 800 µg sublingual Misoprostol in the active management of the third stage of labor, focusing on maternal outcomes, blood loss, side effects, and the need for additional interventions.
Methods: A randomized controlled trial was conducted in the Department of Obstetrics and Gynaecology at Hayatabad Medical Complex from August 1, 2021, to February 1, 2022. A total of 284 women aged 18-40 years with singleton pregnancies were enrolled and randomized into two groups of 142 each. Group A received 800 µg of sublingual Misoprostol, while Group B received 10 IU intravenous Syntocinon at the delivery of the anterior shoulder of the baby. The third stage of labor was managed with early cord clamping and controlled cord traction. Blood loss was meticulously recorded, and patients were monitored for 24 hours postpartum. Data were analyzed using IBM SPSS Statistics version 25, with continuous variables expressed as mean ± standard deviation and categorical variables as frequencies and percentages. Post-stratification analysis utilized an independent sample t-test, with a p-value of ≤ 0.05 considered statistically significant.
Results: The mean age of participants was 29.507±3.24 years in the Misoprostol group and 28.352±3.77 years in the Syntocinon group. Blood loss was slightly lower in the Misoprostol group (242.4 ± 3.72 ml) compared to the Syntocinon group (249.176 ± 4.07 ml). The majority of participants were aged 18-30 years (69.7% in Group A and 71.1% in Group B). No statistically significant differences were observed in blood loss based on age, gestational age, or parity.
Conclusion: Misoprostol offers practical advantages in terms of ease of administration and stability at room temperature, making it a viable alternative, especially in low-resource settings. Both Misoprostol and Syntocinon are effective in managing the third stage of labor, with comparable efficacy in reducing blood loss.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Lindgren L. The Influence of Uterine Motility Upon Cervical Dilatation in Labor. Am J Obstet Gynecol. 1973;117:530.
Weeks A, Neilson JP. Rethinking Our Approach to Postpartum Haemorrhage and Uterotonics. BMJ. 2015;351.
Green L, Knight M, Seeney FM, Hopkinson C, Collins PW, Collis RE, et al. The Epidemiology and Outcomes of Women with Postpartum Haemorrhage Requiring Massive Transfusion with Eight or More Units of Red Cells: A National Cross-Sectional Study. BJOG. 2016;123(13):2164-70.
Begley CM, Gyte GML, Devane D, McGuire W, Weeks A, Biesty LM. Active Versus Expectant Management for Women in the Third Stage of Labour. Cochrane Database Syst Rev. 2019;(2).
Güngördük K, Olgaç Y, Gülseren V, Kocaer M. Active Management of the Third Stage of Labor: A Brief Overview of Key Issues. Turk J Obstet Gynecol. 2018;15(3):188-92.
Numfor E, Fobellah NN, Tochie JN, Njim T, Ndesso SA. Oxytocin Versus Misoprostol Plus Oxytocin in the Prevention of Postpartum Hemorrhage at a Semi-Urban Hospital in Sub-Saharan Africa: A Retrospective Cohort Study. Int J MCH AIDS. 2020;9(3):287-96.
Alam A, Paresh S, Goswami S. A Comparative Study of Efficacy of Oxytocin, Methylergometrine and Misoprostol in Prevention of Post-Partum Hemorrhage. Int J Reprod Contracept Obstet Gynecol. 2017;6:1960-4.
Hassan T, Haider M, Jabeen S, Noor S, Javaid N, Mahnoor T. Comparison of Efficacy of Sublingual Misoprostol and Intravenous Syntometrine in the Active Management of Third Stage of Labour. Ann Punjab Med Coll. 2019;13(4):277-82.
World Health Organization (WHO). WHO Recommendations for Prevention of PPH. Geneva, Switzerland: World Health Organization; [cited 2021 Apr 5]. Available from: https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241548502/en/.
Utah Medical Products, Inc. Intrauterine Pressure Catheters - Intran PLUS IUPCs. 1998-2008; [cited 2008; Available from: http://www.utahmed.com/intran.htm.
Bottoms SF, Hirsch VJ, Sokol RJ. Medical Management of Arrest Disorders of Labor: A Current Overview. Am J Obstet Gynecol. 1987;156:935.
Rouse DJ, Owen J, Hauth JC. Active-Phase Labor Arrest: Oxytocin Augmentation for at Least 4 Hours. Obstet Gynecol. 1999;93:323.
Dombrowski MP, Bottoms SF, Saleh AA, et al. Third Stage of Labor: Analysis of Duration and Clinical Practice. Am J Obstet Gynecol. 1995;172:1279.
Tunçalp O, Hofmeyr GJ, Gulmezoglu AM. Prostaglandins for Preventing Postpartum Haemorrhage. Cochrane Database Syst Rev. 2012;2012(8)
.
Raams TM, Browne JL, Festen-Schrier VJMM, Klipstein-Grobusch K, Rijken MJ. Task Shifting in Active Management of the Third Stage of Labor: A Systematic Review. BMC Pregnancy Childbirth. 2018;18(1):47.
Begley CM, Gyte GM, Devane D, McGuire W, Weeks A, Biesty LM. Active Versus Expectant Management for Women in the Third Stage of Labour. Cochrane Database Syst Rev. 2019;2(2).
Kirz DS, Haag MK. Management of the Third Stage of Labor in Pregnancies Terminated by Prostaglandin E2. Am J Obstet Gynecol. 1989;160:412.
Prendiville W, Elbourne D, Chalmers I. The Effects of Routine Oxytocic Administration in the Management of the Third Stage of Labour: An Overview of the Evidence from Controlled Trials. Br J Obstet Gynaecol. 1988;95:3.
Allen R, O’Brien BM. Uses of Misoprostol in Obstetrics and Gynecology. Rev Obstet Gynecol. 2009;2(3):159-68.
Vimla N, Mittal S, Kumar S, et al. Sublingual Misoprostol Versus Methylergometrine for Active Management of Third Stage of Labor. Int J Gynecol Obstet. 2004;87:1-5.